Graph AI, a California-based artificial intelligence startup specializing in drug safety and pharmacovigilance, has secured $3 million in seed funding, led by Bessemer Venture Partners.
The company intends to use the funds to advance product development, grow its engineering team, and drive global adoption of its automation platform among pharmaceutical firms.
Established in 2024 by Raghav Parvataraju, Vijay Ponukumati, Mohan Konyala, and Ashutosh Bordekar, Graph AI seeks to modernize the detection and reporting of adverse drug events — a domain long dominated by manual, labor-intensive work. The founders bring prior experience from LTI Mindtree, Infosys, ServiceNow, Google, and Cisco.
Graph AI’s core product, Graph Safety, employs context-aware AI to automate functions such as case processing, signal detection, and regulatory reporting, while maintaining human oversight for key decision points.
Pharmacovigilance — a regulatory requirement worldwide — obliges drug safety manufacturers to continuously track and report possible side effects from clinical trials to post-market stages.
Traditionally, pharmaceutical companies outsource this work to large service providers that rely on teams of pharmacology graduates to analyze unstructured information such as medical records, call logs, and legal documents. However, Graph AI claims its technology can make this process up to 90% faster and 70% more efficient, thereby reducing compliance delays and operational costs.
“Life sciences companies still struggle with outdated, fragmented systems that slow decision-making,” the founders said in a joint statement. “We’re building an AI-native safety platform that integrates context, compliance, and intelligence to help organizations achieve safer outcomes and stronger regulatory confidence.”
According to Nithin Kaimal, Bessemer’s India partner and COO, the investment reflects the firm’s belief in AI’s ability to “shift delivery from labor arbitrage to intelligence arbitrage,” turning traditional service-driven models into scalable, technology-led ones.
Graph AI has already rolled out its platform for enterprise clients and is developing a pipeline covering more than 7,000 marketed drugs.
